How can we help you?

De-Escalate

Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial
Description: A pragmatic trial that aims to revisit intermittent androgen deprivation therapy (ADT) in patients with metastatic hormone-naïve prostate cancer.
Study Phase: Phase 3
Principal Investigator: Dr Raheel Khan
Further information

Enquire about a Cancer Clinical Trial

If you would like more information on Cancer Clinical Trials you can contact us.

Make an enquiry